Innovent and SanegeneBio Enter into a Strategic Collaboration Agreement to Develop SGB-3908 for the Treatment of Hypertension
Shots:
- Innovent has signed an agreement with SanegeneBio to co-develop SGB-3908, a siRNA drug candidate targeting angiotensinogen (AGT), for the treatment of hypertension. Both companies will jointly develop SGB-3908 up until certain specified stages
- Under the terms of the agreement, Innovent will receive an exclusive option to pay different option exercise fee to obtain the exclusive development, manufacturing & commercialization license of SGB-3908 in different across the globe. Following Innovent’s option exercise, SanegeneBio will be eligible to receive subsequent milestone payments plus tiered royalties
- The collaboration will combine SanegeneBio’s cutting-edge RNA technology with Innovent’s clinical development experience & commercialization capabilities
Ref: Innovent | Image: Innovent
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Kritika is a content writer at PharmaShots. She is interested in covering recent innovations from the pharma & MedTech industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.
